Products

JOURNAVX

Oral nonopioid indicated for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults

journavxhcp.com Industry Software / Life Sciences & Biotech

AI Benchmark
Monthly visits
97.1K
Down37.6%MoMOct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Creators
Unlinked
No verified creators
Launched
2y ago
2024-04-19 · Est.

Traffic

Monthly visitsData through Oct 2026
Events7 changes

Marketing moves

Launches, search & content, referrals, promotions
  • New product launchLaunch

    Apr 19, 2024 · 2y agoWebsite

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Paid Search48%
  • Display Ads28%
  • Organic Search13%
  • Direct5%
  • Other5%

Countries

  • United States100%

Search

Domain authority —Domain registered 2024-04-19

KeywordMonthly volume
journavx50.9K
suzetrigine14.2K
journavx (suzetrigine)3,190
journavx mechanism of action540
what insurances cover journavx410

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2026-11-04

Key pages

Weekly snapshots

Changes

  1. Nov 11 · 5d ago

    Product format no longer mentioned: otherFeatures

    other→—

    At the time: 97.1K visits/mo6 concurrent moves
  2. Nov 11 · 5d ago

    Homepage tagline changed to “JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults”Positioning

    See how JOURNAVX works→JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults

    At the time: 97.1K visits/mo6 concurrent moves
  3. Nov 1 · 16d ago

    Homepage headline (H1) changed to “JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain, includin...”Positioning

    JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain in adults→JOURNAVX is an oral nonopioid indicated for the treatment of moderate-to-severe acute pain, includin...

    At the time: 97.1K visits/mo6 concurrent moves
  4. Nov 1 · 16d ago

    Removed technology: Acquia PersonalizationFeatures

    Acquia Personalization→—

    At the time: 97.1K visits/mo6 concurrent moves
  5. Nov 1 · 16d ago

    Removed technology: Google AnalyticsFeatures

    Google Analytics→—

    At the time: 97.1K visits/mo6 concurrent moves
  6. Nov 1 · 16d ago

    Adopted technology: Open GraphFeatures

    —→Open Graph

    At the time: 97.1K visits/mo6 concurrent moves

Questions & evidence

How much website traffic does JOURNAVX get?
Vaneform estimates 97.1K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is JOURNAVX and what platforms does it support?
JOURNAVX is catalogued under Life Sciences & Biotech: Oral nonopioid indicated for the treatment of moderate-to-severe acute pain, including postoperative pain, in adults. Supported platforms: Web.

Related products in this category

Industry Software / Life Sciences & Biotech

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.